Comerica Bank Sells 461 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Comerica Bank lessened its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART – Get Rating) by 1.4% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 33,546 shares of the life sciences company’s stock after selling 461 shares during the period. Comerica Bank’s holdings in Integra LifeSciences were worth $1,450,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Wipfli Financial Advisors LLC bought a new position in shares of Integra LifeSciences during the 3rd quarter valued at about $29,000. First Horizon Advisors Inc. bought a new position in shares of Integra LifeSciences during the 2nd quarter valued at about $54,000. Aubrey Capital Management Ltd bought a new position in shares of Integra LifeSciences during the 2nd quarter valued at about $76,000. Covestor Ltd boosted its holdings in shares of Integra LifeSciences by 63.0% during the 1st quarter. Covestor Ltd now owns 1,558 shares of the life sciences company’s stock valued at $100,000 after purchasing an additional 602 shares during the last quarter. Finally, Captrust Financial Advisors boosted its holdings in shares of Integra LifeSciences by 95.0% during the 1st quarter. Captrust Financial Advisors now owns 2,003 shares of the life sciences company’s stock valued at $129,000 after purchasing an additional 976 shares during the last quarter. Institutional investors own 87.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. TheStreet raised shares of Integra LifeSciences from a “c+” rating to a “b-” rating in a report on Tuesday, December 27th. Truist Financial increased their price target on shares of Integra LifeSciences from $52.00 to $58.00 and gave the company a “hold” rating in a report on Tuesday, December 20th. Morgan Stanley increased their price target on shares of Integra LifeSciences from $50.00 to $59.00 and gave the company an “equal weight” rating in a report on Friday, January 6th. JMP Securities lowered their price target on shares of Integra LifeSciences from $85.00 to $75.00 and set a “market outperform” rating for the company in a report on Thursday, October 27th. Finally, StockNews.com assumed coverage on shares of Integra LifeSciences in a report on Wednesday, October 12th. They issued a “buy” rating for the company. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, Integra LifeSciences presently has an average rating of “Hold” and a consensus target price of $58.33.

Integra LifeSciences Stock Performance

Integra LifeSciences stock opened at $56.27 on Monday. The company has a debt-to-equity ratio of 0.86, a current ratio of 3.93 and a quick ratio of 2.91. Integra LifeSciences Holdings Co. has a 1-year low of $40.67 and a 1-year high of $68.29. The firm has a market capitalization of $4.70 billion, a P/E ratio of 27.32, a price-to-earnings-growth ratio of 1.59 and a beta of 1.14. The company’s 50-day moving average is $55.68 and its 200 day moving average is $51.65.

Integra LifeSciences (NASDAQ:IART – Get Rating) last posted its quarterly earnings data on Wednesday, October 26th. The life sciences company reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.14. Integra LifeSciences had a net margin of 11.05% and a return on equity of 16.41%. The company had revenue of $385.19 million for the quarter, compared to analyst estimates of $377.79 million. Research analysts forecast that Integra LifeSciences Holdings Co. will post 3.33 EPS for the current year.

About Integra LifeSciences

(Get Rating)

Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical and Tissue Technologies segments. The Codman Specialty Surgical segment refers to the company’s neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care, such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment, and the precision tools and instruments business, which sells instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices.